France · Source-listed medicine information

France / CIS 62793992

LIDOCAÏNE KABI 10 mg/mL, solution injectable

solution injectable · infiltration / intramusculaire / intraveineuse / péridurale / périneurale / sous-cutanée

Directory source checks passedOriginal source language: French

Source data retrieved: 2026-09-17. Clinical review is not yet available.

Formsolution injectable
Routeinfiltration / intramusculaire / intraveineuse / péridurale / périneurale / sous-cutanée
Ingredient entries2
CountryFrance

Product identity

At a glance

Authorisation holder
FRESENIUS KABI FRANCE
Authorisation status
Autorisation active
Market status
Commercialisée
Country
France
Source reference
CIS 62793992

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Source composition entries for LIDOCAÏNE KABI 10 mg/mL, solution injectable
IngredientStrength / referenceSource role
LIDOCAÏNEsolution8,11 mg1 mL de solutionFTGroup 1
LIDOCAÏNE (CHLORHYDRATE DE) MONOHYDRATÉsolution10 mg1 mL de solutionSAGroup 1

Pack references

Presentations (3)

100 ampoules polyéthylène basse densité (PEBD) de 5 mL

CIP13 3400955056898

Présentation active · Déclaration d'arrêt de commercialisation
50 ampoules polyéthylène basse densité (PEBD) de 20 mL

CIP13 3400955056904

Présentation active · Déclaration de commercialisation
100 ampoule(s) polyéthylène basse densité (PEBD) de 10 ml

CIP13 3400955058953

Présentation active · Déclaration de commercialisation

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Open the official product entryBDPM · CIS 62793992 · Opens in a new tab

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Source files and their retrieval dates
Source fileRetrievedSource file modified
fr_products.txtNot supplied
fr_composition.txtNot supplied
fr_packs.txtNot supplied

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.

Our sources and review process →